According to a Washington Post report, the general manager of a plan that involved a production of 15 million doses of Johnson & Johnson coronavirus vaccine received a 51% increase in compensation.
Emerging Biosolutions CEO Robert Kramer received $ 5.6 million in 2020, according to a public document reviewed Friday.
The company executive received a salary of $ 893,000, $ 1.4 million for stock options, $ 2.1 million for the allotment of shares and a $ 1.2 million bonus, according to the Post.
According to the filing, the company raised Kramer’s salary after the company’s manufacturing business expanded and the CEO responded to the pandemic.
The company also reported a 41% increase in revenue in 2020. Kramer became the company’s CEO in 2019 and has been with the company since 2012, according to the newspaper.
Emergents saw this increase in growth last year, mainly due to a federal contract that awarded the company $ 628 million to help fight the coronavirus pandemic, according to the newspaper.
The Post noted, however, that the bonuses were prior to the the company’s Maryland plant contaminated 15 million doses of Johnson & Johnson vaccine.
In late March, problems with vaccine production at the Emergent plant became public after the Johnson & Johnson vaccine was contaminated with ingredients from the AstraZeneca vaccine, according to the Post.
AstraZeneca materials have been completely moved from the facility and Johnson & Johnson is in charge of supervising the plant.
The White House warned Friday that states will receive a substantially lower amount of the Johnson & Johnson vaccine over the next few weeks as a result of the setback.
The New York Times earlier this week reported that there was a high risk of cross-contamination Found in facility audits last year. It was also reported that the staff was not trained.
The Hill has contacted Emergent Solutions to comment.